


Figure S19



Siltuximab treatment does not decrease leukemic burden in NSG^{spln}- mice engrafted with human AML. NSG^{spln}- mice were engrafted with indicated human AML samples. Control antibody and siltuximab treatment began on day 3 after engraftment and continued every 72 hours until the end of the experiment. Human AML disease burden was examined at week 6-8 in the BM of NSG^{spln}- mice engrafted with (A) SU540, (B) SU575, (C) SU555, (D) SU351. AML burden was assessed in the PB of NSG^{spln}- mice engrafted with (E) SU555 and (F) SU351. N.S. = not significant. N = 5 for all experiments above.